Instrument Inactif

Autres langues Vivesto AB OTC Markets

Actions

OASMY

US67421W1099

Produits pharmaceutiques

Autres langues

24/09	Vivesto presents Paccal Vet data at the Veterinary Cancer Society Annual Conference 2026
24/09	Vivesto AB Presents Paccal Vet Data At The Veterinary Cancer Society Annual Conference 2026
17/09	Vivesto: Positive top-line results in cat study
17/09	Vivesto reports positive Paccal Vet cat topline results supporting continued clinical development
17/09	Vivesto Reports Positive Paccal Vet Cat Topline Results Supporting Continued Clinical Development
15/09	Vivesto: Positive top-line results in dog study
15/09	Vivesto’s positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet
15/09	Vivesto AB Reports Positive Topline Results from Clinical Pilot Study Evaluating Paccal Vet in Dogs with Splenic Hemangiosarcoma Following Splenectomy
13/08	Vivesto: Largely a non-event, key readouts ahead – Q2 review
13/08	Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
01/07	Vivesto: Cat study enrolment completed, results expected in Q4
01/07	Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose
01/07	Vivesto Completes Recruitment in Paccal Vet Dose-Finding Study in Cats and Determines Maximum Tolerated Dose
26/06	Vivesto: Paccal Vet top-line results expected in Q3
26/06	Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026
26/06	Vivesto Completes Recruitment in Paccal Vet Dog Pilot Study
16/06	Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study
16/06	Vivesto: Positive data for Cantrixil
16/06	Vivesto reports positive results from i.v. Cantrixil PK/toxicology study
05/06	Sweden's Vivesto Names New Finance Chief
05/06	Vivesto appoints Björn Svanström as CFO
05/06	Vivesto AB Announces Chief Financial Officer Changes
29/05	New number of shares and votes in Vivesto
26/05	Vivesto: Minor model adjustments
13/05	Vivesto sets record date for reverse share split as May 21, 2026